The EIF5A2 Knockout K-562 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human chronic myelogenous leukemia (CML) cell line K-562, with targeted disruption of the EIF5A2 gene. This polyclonal pool encompasses a spectrum of editing events, offering a versatile tool for functional genomics studies without the clonal selection bias inherent to monoclonal lines. The knockout product format facilitates scalable experiments while maintaining genetic heterogeneity representative of the original edited population.
The K-562 host cell line was established from a 53-year-old female with CML in blast crisis and is characterized by the expression of the BCR-ABL1 fusion oncoprotein. As an erythroleukemic line, K-562 cells serve as a widely employed model for hematopoietic differentiation, oncogenic signaling, and leukemogenesis research. Their robust proliferation and suspension growth make them amenable to high-throughput screening and molecular analysis.
EIF5A2 encodes a translation elongation factor that undergoes a unique post-translational modification, hypusination, catalyzed by deoxyhypusine synthase (DHPS) and deoxyhypusine hydroxylase (DOHH). This modification permits association with the 80S ribosome, where EIF5A2 facilitates the translation of specific mRNAs encoding proteins involved in cell cycle progression and epithelial-mesenchymal transition (EMT). EIF5A2 operates downstream of the MYC and mTORC1 signaling pathways, with mTORC1 regulating its expression and activity via effectors such as 4E-BP1 and S6K1. Key downstream targets of EIF5A2-mediated translational control include the G1 cyclin CCND1, the CDK inhibitor CDKN1B, matrix metalloproteinases MMP2 and MMP9, and the EMT marker Vimentin. Additionally, EIF5A2 interacts with the nuclear export factor XPO1, linking ribosome-associated translation to nucleocytoplasmic transport dynamics.
In the K-562 leukemic context, EIF5A2 dysregulation is pertinent given its oncogenic roles in promoting proliferation, survival, and metastatic potential. The BCR-ABL1 oncoprotein activates multiple signaling cascades, including MYC and mTOR, which may converge on EIF5A2 to drive leukemic cell growth. Disruption of EIF5A2 in this model permits dissection of its contribution to CML blast crisis pathology, including possible effects on cell cycle deregulation and apoptosis resistance. The polyclonal knockout pool can be used to interrogate EIF5A2-dependent translation of specific mRNAs that support leukemogenesis, providing insights into the molecular interplay between oncogenic kinases and the translational machinery.
This EIF5A2 knockout K-562 polyclonal cell product is designed for diverse research applications in cancer biology, translational control, and leukemia modeling. Users may employ it for Western blotting and RT-qPCR to confirm protein and transcript ablation, proliferation and apoptosis assays to assess growth phenotypes, and migration/invasion assays to evaluate EMT-related behaviors. The polyclonal format is compatible with polysome profiling to analyze ribosome occupancy on target mRNAs and with RNA-seq to identify global transcriptomic changes. Drug sensitivity assays can be performed to explore the impact of EIF5A2 loss on response to agents targeting BCR-ABL1, mTOR, or other pathway components. For further technical information or inquiries regarding this model, please contact Ascent Research.
